Introduction
============

Digestive system cancers, including esophageal, gastric, hepatocellular, bowel, pancreatic, gallbladder and anal cancers, are the most common types of cancer worldwide. There are an estimated 3.4 million new cases diagnosed worldwide each year and the mortality rates have increased over the past decade ([@b1-etm-09-01-0219]). Although the exact mechanism of carcinogenesis remains to be fully understood, accumulating evidence has confirmed that certain risk factors (such as dietary, ethnic and socioeconomic factors) and interactions between genetic and environmental factors may play important roles in the pathogenesis of these types of cancer ([@b2-etm-09-01-0219],[@b3-etm-09-01-0219]).

Serine/threonine kinase 15 (STK15, also known as Aurora-A or AURKA) is a centrosome-localized serine/threonine kinase that is involved in cell cycle regulation, particularly the passage from G~2~ to M, through the formation of mitotic spindles ([@b4-etm-09-01-0219]). The STK15 gene, which consists of nine exons, is located on chromosome 20q13.2, a region frequently amplified and overexpressed in various types of human cancer ([@b5-etm-09-01-0219]). STK15 has been reported to be overexpressed in numerous types of malignancies, including colorectal and pancreatic cancers ([@b6-etm-09-01-0219],[@b7-etm-09-01-0219]). Considerable evidence indicates that overexpression of the STK15 gene results in centrosome amplification, chromosomal instability, aneuploidy and transformation ([@b8-etm-09-01-0219]). Two non-synonymous polymorphisms, 91T\>A (rs2273535) and 169G\>A (rs1047972), have been identified in the STK15 gene. A thymine (T)/adenine (A) polymorphism located at nucleotide position 91 encodes a phenylalanine (Phe)-to-isoleucine (Ile) substitution at amino acid position 31. A guanine (G)/A polymorphism at nucleotide 169 encodes a valine (Val)-to-Ile substitution at amino acid position 57. The two polymorphisms are located within two conserved motifs in the N-terminus region of the STK15 gene ([@b9-etm-09-01-0219]). It has been revealed that the A allele of the 91T\>A (31Ile\>Phe) polymorphism is preferentially amplified and more potent than the T allele in leading to aneuploidy and transformation ([@b8-etm-09-01-0219]). Furthermore, the 169G\>A (57Val\>Ile) polymorphism was found to affect the kinase activity of aurora kinase A ([@b10-etm-09-01-0219]).

Studies have suggested the presence of an association between the two coding polymorphisms in the STK15 gene and an increased risk of digestive system cancers ([@b10-etm-09-01-0219]--[@b23-etm-09-01-0219]); however, the results have been inconsistent. The aim of the present study was therefore to conduct a meta-analysis to evaluate the association between the two STK15 polymorphisms and susceptibility to digestive system cancers.

Materials and methods
=====================

Search strategy
---------------

The electronic literature databases of PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang and VIP were searched for all relevant articles. The last search update was February 18, 2014, using the search terms: 'Serine/threonine kinase 15 or STK15 or Aurora-A or AURKA' and 'genetic polymorphism or polymorphisms or variant' and 'digestive system cancer or gastric cancer or colorectal cancer or hepatocellular carcinoma or pancreatic cancer or esophageal cancer'. The search was restricted to humans without language exclusions. Additional studies were identified by a manual search of the references from the original or review articles on this topic.

Inclusion and exclusion criteria
--------------------------------

Studies included in this meta-analysis were selected according to the following criteria: i) Studies that evaluated the association between the STK15 polymorphisms (91T\>A or 169G\>A) and digestive system cancers; ii) studies that had a case-control design; and iii) studies that had a detailed genotype frequency of cases and controls or that had presented sufficient data for this to be calculated from the article text. The major exclusion criteria were i) case-only studies, case reports and review articles; ii) studies without raw data of the STK15 genotype; and iii) repetitive publications.

Data extraction
---------------

For each study, the following data were extracted independently by two investigators: The name of the first author, age and gender of the subjects, year of study publication, country of origin, ethnicity, source of controls, genotype methods, number of cases and controls, and the Hardy-Weinberg equilibrium (HWE) in the controls (P-value). The results were compared and disagreements were discussed among all authors and resolved with consensus.

Statistical analysis
--------------------

The HWE was evaluated for each study using an internet-based HWE calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) ([@b24-etm-09-01-0219]). The risk of digestive system cancers associated with the STK15 polymorphisms was estimated for each study by the odds ratio (OR) and 95% confidence interval (CI). Four different ORs were calculated: The dominant model (variant homozygote + heterozygote versus wild-type homozygote), the recessive model (variant homozygote versus heterozygote + wild-type homozygote), heterozygote comparison (heterozygote versus wild-type homozygote) and homozygote comparison (variant homozygote versus wild-type homozygote). A χ^2^-test-based Q statistic test was performed to assess the heterogeneity between studies ([@b25-etm-09-01-0219]). The effect of heterogeneity was also quantified by the I^2^ test. When a significant Q test (P\>0.05) or I^2^ value \<50% indicated homogeneity across the studies, the fixed effects model was used ([@b26-etm-09-01-0219]); otherwise, the random effects model was used ([@b27-etm-09-01-0219]). Stratification analyses on ethnicity and tumor type were subsequently performed. Analysis of sensitivity was performed to evaluate the stability of the results. Finally, potential publication bias was investigated using Begg's funnel plot and Egger's regression test ([@b28-etm-09-01-0219],[@b29-etm-09-01-0219]). P\<0.05 was considered to indicate a statistically significant difference.

All analyses were performed using the Cochrane Collaboration RevMan 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2012) and STATA package version 12.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Study characteristics
---------------------

The search strategy retrieved 72 potentially relevant studies. According to the inclusion criteria, 14 studies ([@b10-etm-09-01-0219]--[@b23-etm-09-01-0219]) with full-text were included in the present meta-analysis and 58 studies were excluded. The flow chart of the study selection is summarized in [Fig. 1](#f1-etm-09-01-0219){ref-type="fig"}. Since the study by Ewart-Toland *et al* ([@b16-etm-09-01-0219]) included two populations, these populations were treated separately in the current meta-analysis ([Tables I](#tI-etm-09-01-0219){ref-type="table"} and [II](#tII-etm-09-01-0219){ref-type="table"}); as such, there were 15 case-control studies from 14 publications with 7,619 cases and 7,196 controls concerning the 91T\>A polymorphism and four studies with 826 cases and 713 controls concerning the 169G\>A polymorphism. Of the 15 eligible studies, 10 studies ([@b11-etm-09-01-0219],[@b12-etm-09-01-0219],[@b14-etm-09-01-0219],[@b10-etm-09-01-0219],[@b16-etm-09-01-0219]--[@b19-etm-09-01-0219],[@b22-etm-09-01-0219]) were written in English and five studies ([@b13-etm-09-01-0219],[@b15-etm-09-01-0219],[@b20-etm-09-01-0219],[@b21-etm-09-01-0219],[@b23-etm-09-01-0219]) in Chinese; nine studies ([@b12-etm-09-01-0219],[@b13-etm-09-01-0219],[@b15-etm-09-01-0219],[@b10-etm-09-01-0219],[@b18-etm-09-01-0219]--[@b21-etm-09-01-0219],[@b23-etm-09-01-0219]) were conducted on Asian populations, five studies ([@b11-etm-09-01-0219],[@b14-etm-09-01-0219],[@b16-etm-09-01-0219],[@b17-etm-09-01-0219],[@b22-etm-09-01-0219]) on Caucasian populations and one study ([@b16-etm-09-01-0219]) on a mixed population. Four tumor types were addressed: Six studies ([@b12-etm-09-01-0219],[@b15-etm-09-01-0219],[@b10-etm-09-01-0219],[@b19-etm-09-01-0219]--[@b21-etm-09-01-0219]) focused on esophageal cancer; six studies ([@b14-etm-09-01-0219],[@b16-etm-09-01-0219],[@b17-etm-09-01-0219],[@b22-etm-09-01-0219],[@b23-etm-09-01-0219]) on colorectal cancer; two studies ([@b13-etm-09-01-0219],[@b18-etm-09-01-0219]) on gastric cancer and one study ([@b11-etm-09-01-0219]) on hepatocellular carcinoma. The distribution of genotypes among the controls was consistent with the HWE for all selected studies, with the exception of three ([@b12-etm-09-01-0219],[@b10-etm-09-01-0219],[@b21-etm-09-01-0219]).

Quantitative data synthesis
---------------------------

Fifteen studies reported an association between the 91T\>A polymorphism and susceptibility to digestive system cancers. Overall, a significantly increased risk was found under the recessive model (OR, 1.19; 95% CI, 1.07--1.31) ([Fig. 2](#f2-etm-09-01-0219){ref-type="fig"}), while no notable associations were observed under the three other models (dominant model: OR, 1.02; 95% CI, 0.87--1.21; TA versus TT: OR, 0.97; 95% CI, 0.83--1.14; AA versus TT: OR, 1.12; 95% CI, 0.89--1.42).

In the subgroup analysis by ethnicity, a significant association was detected in the Asian population under the recessive model (OR, 1.21; 95% CI, 1.08--1.36) but under the other three models. No association was observed in the Caucasian or mixed populations.

Stratification by tumor type indicated that the 91T\>A polymorphism was associated with an increased risk of esophageal and colorectal cancers under the recessive model (OR, 1.19; 95% CI, 1.03--1.38; and OR, 1.24; 95% CI, 1.04--1.46; respectively); however, no significant association was detected for gastric cancer. Only one study focused on hepatocellular cancer and the results showed that the STK15 91T\>A polymorphism may be a genetic susceptibility factor for hepatocellular carcinoma ([Table III](#tIII-etm-09-01-0219){ref-type="table"}).

Four studies reported an association between the 169G\>A polymorphism and the risk of digestive system cancers. The combined results based on all the studies revealed no significant associations among the studies with any of the genetic models (dominant model: OR, 1.02; 95% CI, 0.82--1.28; recessive model: OR, 1.27; 95% CI, 0.25--6.49; GA versus GG: OR, 1.13; 95% CI, 0.90--1.43; AA versus GG: OR, 1.45; 95% CI, 0.29--7.22). In the subgroup analysis by ethnicity, similar results were demonstrated in the Asian and Caucasian populations ([Table III](#tIII-etm-09-01-0219){ref-type="table"}).

Heterogeneity and sensitivity analyses
--------------------------------------

Substantial heterogeneities were observed among the studies for the association between the risk of digestive system cancers and the 91T\>A (dominant model: I^2^=68%, P\<0.0001; TA versus TT: I^2^=63%, P=0.0005; AA versus TT: I^2^=58%, P=0.002) and 169G\>A (recessive model: I^2^=58%, P=0.07; AA versus TT: I^2^=56%, P=0.08) STK19 polymorphisms. The source of the heterogeneity for the genetic model comparisons by ethnicity and tumor site was subsequently analyzed. For the 91T\>A polymorphism, the heterogeneity was partially decreased or removed in colorectal and gastric cancers and Caucasian populations; however, significant heterogeneity remained for esophageal cancer and Asian populations. For the 169G\>A polymorphism, the heterogeneity significantly decreased when the study by Kimura *et al* ([@b10-etm-09-01-0219]) was excluded from the analysis. A sensitivity analysis was performed to evaluate the stability of the results. Since the statistical significance of the results did not change when any single study was omitted, the stability of the results was confirmed.

Publication bias
----------------

Begg's funnel plot and Egger's tests were used to address potential publication bias in the available literature. The shape of the funnel plots did not show any evidence of funnel plot asymmetry (data not shown). Egger's test also demonstrated that there was no statistical significance in the evaluation of publication bias (dominant model, P=0.991; TA versus TT, P=0.721; AA versus TT, P=0.925; recessive model, P=0.835).

Discussion
==========

STK15, a member of the Aurora family, plays a vital role in bipolar mitotic spindle formation and regulates chromosome segregation in mammalian cells ([@b30-etm-09-01-0219]). It has been reported that STK15 is overexpressed in numerous types of cancer, including colorectal, pancreatic, breast and prostate ([@b6-etm-09-01-0219],[@b7-etm-09-01-0219],[@b31-etm-09-01-0219],[@b32-etm-09-01-0219]). Although the mechanism remains unclear, it is believed that the polymorphism may partially affect STK15 expression and therefore modify its function. Ewart-Toland *et al* ([@b8-etm-09-01-0219]) suggested that the STK15 91T\>A polymorphism (T→A) variant changed the activity of the STK15 box 1, leading to an inhibition of p53 binding and the decreased degradation of STK15. It was further suggested that the stabilized overexpression of STK15 led to centrosome amplification, improper cytokinesis, chromosomal instability and the promotion of tumorigenesis ([@b8-etm-09-01-0219]). To date, a number of studies have investigated the association between STK15 polymorphisms and the risk of cancers, particularly cancers of the digestive system ([@b10-etm-09-01-0219]--[@b23-etm-09-01-0219]); however, the results have been inconsistent. In a study from Turkey, Akkiz *et al* ([@b11-etm-09-01-0219]) reported that the STK15 91T\>A polymorphism may be a genetic susceptibility factor for hepatocellular carcinoma. Similarly, Hienonen *et al* ([@b17-etm-09-01-0219]) observed that the STK15 91T\>A polymorphism was a low penetrance colorectal cancer susceptibility factor in Finnish populations; however, Webb *et al* ([@b22-etm-09-01-0219]) suggested that there was no association between the polymorphism and colorectal cancer susceptibility based on their results. With regard to the 169G\>A polymorphism, Ju *et al* ([@b18-etm-09-01-0219]) reported that the 169G\>A polymorphism in the STK15 gene was associated with the progression of gastric cancer; however, in a study from China, Chen ([@b13-etm-09-01-0219]) failed to detect any association between the 169G\>A polymorphism and the risk of gastric cancer.

Recently, two meta-analyses ([@b33-etm-09-01-0219],[@b34-etm-09-01-0219]) evaluated the association between the STK15 91T\>A polymorphism and risk of cancer, and reported that the STK15 91T\>A polymorphism may be a risk factor for cancer. In comparison, the present study conducted a comprehensive literature search of different databases and included several additional studies. Furthermore, the association between the 169G\>A polymorphism and the risk of digestive system cancers was explored. In the current meta-analysis, 15 studies were pooled to examine the association between the two STK15 polymorphisms and risk of digestive system cancers. The results demonstrated that there was a significant association between the STK15 91T\>A polymorphism and the risk of digestive system cancers.

In the subgroup analysis by ethnicity, there was a significant association in Asian descent, but not in Caucasian and mixed populations. Different genetic backgrounds and environmental exposures among the different ethnic groups may contribute to this discrepancy ([@b35-etm-09-01-0219]). When stratified by tumor type, the 91T\>A polymorphism was associated with an increased risk of esophageal and colorectal cancers, but not gastric cancer. Only one study focused on hepatocellular carcinoma and the results revealed that the STK15 91T\>A polymorphism may be a genetic susceptibility factor for hepatocellular carcinoma; however, since only a few studies on gastric cancer and hepatocellular carcinoma were included, these results should be interpreted with caution, and further studies are required.

No significant association was found between the 169G\>A polymorphism and the risk of digestive system cancers in any of the genetic models. When stratified according to ethnicity, similar results were observed in Asian and Caucasian populations. This lack of association may have been due to the limited literature (only four studies) in the present meta-analysis. The conclusions should therefore be considered sensibly. Furthermore, cancer is a multi-factorial disease that results from complex interactions between a number of environmental and genetic factors (gene-gene or gene-environment). Not all of the studies included, however, analyzed the same environmental or genetic factors and, due to lack of individual data in the present review, more detailed analyses, such as analyses of joint effects with other risk factors or gene-gene or gene-environment interactions, were not able to be performed.

Heterogeneity is a potential problem when interpreting the results of all meta-analyses ([@b36-etm-09-01-0219]). In the current meta-analysis, heterogeneity was observed in the overall comparison for certain genetic models. When stratified by ethnicity and tumor site, the heterogeneity was partially decreased or removed in colorectal and gastric cancers and Caucasian populations; however, heterogeneity remained for esophageal cancer and Asian populations. For the 169G\>A polymorphism, the heterogeneity significantly decreased when the study by Kimura *et al* ([@b10-etm-09-01-0219]) was excluded from analysis. These results suggest that the ethnic difference, different tumor types and particular study type may be the source of heterogeneity in the present meta-analysis. When sensitivity analyses were conducted by successively excluding one study, the estimated pooled OR changed little, strengthening the results from the meta-analysis. Furthermore, no publication bias was observed, highlighting the possibility of true results.

The current meta-analysis has limitations that require acknowledgement. Firstly, due to incomplete raw data or publication limitations, certain relevant studies were unable to be included in the present analysis. Secondly, the results were based on unadjusted estimates, which may cause serious confounding bias. Thirdly, the data from the European populations were relatively small and significant heterogeneity was observed in certain models, which may have resulted in failure to confirm marginal associations.

In conclusion, the present meta-analysis suggests that the STK15 gene 91T\>A polymorphism, but not the 169G\>A polymorphism, may be a risk factor for digestive system cancers, particularly for esophageal and colorectal cancers.

![Flow chart showing the study selection procedure. STK15, serine/threonine kinase 15.](ETM-09-01-0219-g00){#f1-etm-09-01-0219}

![Forest plots for the association between the serine/threonine kinase 15 gene 91T\>A polymorphism and digestive system cancers risk under a recessive model. CI, confidence interval.](ETM-09-01-0219-g01){#f2-etm-09-01-0219}

###### 

Characteristics of studies included in the meta-analysis.

  A, Studies on the 91T\>A polymorphism                                                                            
  ---------------------------------------- ------- ------------- ----------- ---------------- -------------------- ----------------------------
  Akkiz ([@b11-etm-09-01-0219])            2010    Turkey        Caucasian   Hepatocellular   HB                   PCR-RFLP
  Chava ([@b12-etm-09-01-0219])            2011    India         Asian       Esophageal       NR                   PCR
  Chen L ([@b13-etm-09-01-0219])           2005    China         Asian       Gastric          HB                   PCR-RFLP
  Chen JY ([@b14-etm-09-01-0219])          2007    USA           Caucasian   Colorectal       HB                   Direct sequencing
  Chen XB ([@b15-etm-09-01-0219])          2009    China         Asian       Esophageal       PB                   PCR-RFLP
  Ewart-Toland ([@b16-etm-09-01-0219])     2005a   USA           Mixed       Colorectal       PB                   PCR-RFLP
  Ewart-Toland ([@b16-etm-09-01-0219])     2005b   Scotland      Caucasian   Colorectal       PB                   PCR-RFLP
  Hienonen ([@b17-etm-09-01-0219])         2006    Finland       Caucasian   Colorectal       PB                   Direct sequencing
  Ju ([@b18-etm-09-01-0219])               2006    South Korea   Asian       Gastric          HB                   Mass ARRAY
  Kimura ([@b10-etm-09-01-0219])           2005    Japan         Asian       Esophageal       HB                   PCR
  Miao ([@b19-etm-09-01-0219])             2004    China         Asian       Esophageal       PB                   PCR-RFLP
  Sang ([@b20-etm-09-01-0219])             2012    China         Asian       Esophageal       HB                   MALDI-TOF MS
  Wang ([@b21-etm-09-01-0219])             2007    China         Asian       Esophageal       PB                   PCR-RFLP
  Webb ([@b22-etm-09-01-0219])             2006    UK            Caucasian   Colorectal       PB                   Illuminasentric bead array
  Zhang ([@b23-etm-09-01-0219])            2006    China         Asian       Colorectal       PB                   PCR-RFLP
                                                                                                                   
  B, Studies on the 169G\>A polymorphism                                                                           
                                                                                                                   
  First author (ref.)                      Year    Country       Ethnicity   Tumor type       Source of controls   Genotype methods
                                                                                                                   
  Chen L ([@b12-etm-09-01-0219])           2005    China         Asian       Gastric          HB                   PCR-RFLP
  Chen JY ([@b13-etm-09-01-0219])          2007    USA           Caucasian   Colorectal       HB                   Direct sequencing
  Ju ([@b17-etm-09-01-0219])               2006    South Korea   Asian       Gastric          HB                   Mass ARRAY
  Kimura ([@b18-etm-09-01-0219])           2005    Japan         Asian       Esophageal       HB                   PCR

NR, not reported; HB, hospital-based; PB, population-based; MALDI-TOF MS, matrix-assisted laser desorption/ionization time of flight mass spectrometry; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; ref., reference.

###### 

Patient data for studies included in the meta-analysis.

  A, Studies on the 91T\>A polymorphism                                                                                                                                                                                                                 
  ---------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------------------- ---------- ----------- ------------ --------- ------------ --------------
  Akkiz ([@b11-etm-09-01-0219])            58 (20--81)[a](#tfn2-etm-09-01-0219){ref-type="table-fn"}   58 (20--81)[a](#tfn2-etm-09-01-0219){ref-type="table-fn"}   106/22                    106/22     128/128     77/99        47/27     4/2          0.919
  Chava ([@b12-etm-09-01-0219])            56.03                                                       NR                                                          NR                        NR         50/150      22/81        28/66     0/3          0.012
  Chen L ([@b13-etm-09-01-0219])           49.04±12.89[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}   51.66±16.12[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}   45/23                     38/37      68/75       5/10         27/32     36/33        0.615
  Chen JY ([@b14-etm-09-01-0219])          43.0±12.7[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}     44.8±12.0[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}     36/24                     27/38      60/65       44/38        13/21     3/6          0.236
  Chen XB ([@b15-etm-09-01-0219])          NR                                                          NR                                                          178/10                    307/17     188/324     43/38        79/168    66/118       0.060
  Ewart-Toland ([@b16-etm-09-01-0219])     NR                                                          NR                                                          NR                        NR         344/448     200/279      121/148   23/21        0.809
  Ewart-Toland ([@b16-etm-09-01-0219])     NR                                                          NR                                                          NR                        NR         1675/1038   1031/630     558/368   86/40        0.126
  Hienonen ([@b17-etm-09-01-0219])         68 (32--90)[a](#tfn2-etm-09-01-0219){ref-type="table-fn"}   NR                                                          109/126                   NR         235/94      122/46       94/43     19/5         0.208
  Ju ([@b18-etm-09-01-0219])               57.7±12.6[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}     52.4±8.7[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}      339/162                   289/138    501/427     75/58        215/190   211/179      0.504
  Kimura ([@b10-etm-09-01-0219])           NR                                                          NR                                                          NR                        NR         197/146     29/12        103/82    65/52        0.010
  Miao ([@b19-etm-09-01-0219])             58.3±9.6[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}      57.5±9.5[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}      460/196                   443/213    656/656     58/91        290/316   308/249      0.560
  Sang ([@b20-etm-09-01-0219])             NR                                                          NR                                                          NR                        NR         380/380     173/153      161/188   46/39        0.089
  Wang ([@b21-etm-09-01-0219])             59.8±9.7[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}      58.8±7.9[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}      202/94                    202/100    296/302     34/36        103/111   159/155      0.026
  Webb ([@b22-etm-09-01-0219])             61±11.4[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}       59±10.9[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}       1471/1087                 836/1844   2558/2680   1564/1667    880/888   114/125      0.628
  Zhang ([@b23-etm-09-01-0219])            57.0±11.0[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}     57.4±9.6[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}      171/112                   170/113    283/283     30/42        111/137   142/104      0.775
                                                                                                                                                                                                                                                        
  B, Studies on the 169G\>A polymorphism                                                                                                                                                                                                                
                                                                                                                                                                                                                                                        
                                           Age (years)                                                 Gender (male/female)                                        Genotype (case/control)                                                              
                                                                                                                                                                                                                                                        
  First author (ref.)                      Case                                                        Control                                                     Case                      Control    Total       WT Ho (GG)   Ht (GA)   VR Ho (AA)   P-value~HWE~
                                                                                                                                                                                                                                                        
  Chen L ([@b13-etm-09-01-0219])           49.04±12.89[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}   51.66±16.12[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}   45/23                     38/37      68/75       49/61        19/11     0/3          0.019
  Chen JY ([@b14-etm-09-01-0219])          43.0±12.7[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}     44.8±12.0[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}     36/24                     27/38      60/65       39/43        20/20     1/2          0.859
  Ju ([@b18-etm-09-01-0219])               57.7±12.6[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}     52.4±8.7[b](#tfn3-etm-09-01-0219){ref-type="table-fn"}      339/162                   289/138    501/427     387/414      100/104   14/9         0.409
  Kimura ([@b10-etm-09-01-0219])           NR                                                          NR                                                          NR                        NR         197/146     118/99       65/47     14/0         0.020

Presented as the mean (range);

presented as the mean ± standard deviation;

HWE, Hardy-Weinberg equilibrium; NR, not reported; Ht, heterozygote; VR Ho, variant homozygote; WT Ho, wild-type homozygote; ref., reference.

###### 

Summary of the ORs of the serine/threonine kinase 15 polymorphisms and risk of digestive system cancers.

  A, Studies on the 91T\>A polymorphism                                                                                                                                                                                                                                                                                                                                                                                                        
  ---------------------------------------- ------------------------------------------------- ------------------- ------------------------------------------------------- ----------------- -------------------- ------------------------------------------------------- ------ ------------------- ------------------------------------------------------- ------ -------------------- ------------------------------------------------------- ------
  Total                                    15                                                1.02 (0.87--1.21)   \<0.0001                                                68                1.19 (1.07--1.31)    0.16                                                    26     0.97 (0.83--1.14)   0.0005                                                  63     1.12 (0.89--1.42)    0.002                                                   58
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Asian                                   9                                                 0.99 (0.73--1.35)   0.0002                                                  73                1.21 (1.08--1.36)    0.10                                                    40     0.92 (0.69--1.22)   0.003                                                   66     1.07 (0.74--1.55)    0.0005                                                  71
   Caucasian                               5                                                 1.04 (0.83--1.29)   0.01                                                    68                1.08 (0.88--1.32)    0.37                                                    6      1.02 (0.81--1.28)   0.01                                                    68     1.08 (0.88--1.33)    0.36                                                    9
   Mixed                                   1                                                 1.19 (0.89--1.58)   NA                                                      NA                1.46 (0.79--2.68)    NA                                                      NA     1.14 (0.84--1.54)   NA                                                      NA     1.12 (0.99--1.28)    NA                                                      NA
  Tumor type                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Esophageal                              6                                                 0.90 (0.59--1.37)   0.0001                                                  80                1.19 (1.03--1.38)    0.24                                                    26     0.85 (0.57--1.28)   0.0007                                                  77     0.91 (0.55--1.53)    0.0006                                                  77
   Colorectal                              6                                                 1.03 (0.95--1.12)   0.20                                                    31                1.24 (1.04--1.46)    0.08                                                    49     1.01 (0.93--1.10)   0.37                                                    8      1.18 (0.98--1.42)    0.15                                                    39
   Gastric                                 2                                                 0.97 (0.68--1.37)   0.20                                                    39                1.06 (0.83--1.35)    0.33                                                    0      0.94 (0.65--1.36)   0.30                                                    5      1.00 (0.69--1.45)    0.17                                                    48
   Hepatocellular                          1                                                 2.26 (1.31--3.90)   NA                                                      NA                2.03 (0.37--11.30)   NA                                                      NA     2.24 (1.28--3.92)   NA                                                      NA     2.57 (0.46--14.41)   NA                                                      NA
                                                                                                                                                                                                                                                                                                                                                                                                                                               
  B, Studies on the 169G\>A polymorphism                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                             Dominant model      Recessive model                                         Ht versus WT Ho   VR versus WT Ho                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Variables                                N[a](#tfn5-etm-09-01-0219){ref-type="table-fn"}   OR (95% CI)         P-value[b](#tfn6-etm-09-01-0219){ref-type="table-fn"}   I^2^              OR (95% CI)          P-value[b](#tfn6-etm-09-01-0219){ref-type="table-fn"}   I^2^   OR (95% CI)         P-value[b](#tfn6-etm-09-01-0219){ref-type="table-fn"}   I^2^   OR (95% CI)          P-value[b](#tfn6-etm-09-01-0219){ref-type="table-fn"}   I^2^
                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Total                                    4                                                 1.02 (0.82--1.28)   0.13                                                    47                1.27 (0.25--6.49)    0.07                                                    58     1.13 (0.90--1.43)   0.45                                                    0      1.45 (0.29--7.22)    0.08                                                    56
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Asian                                   3                                                 0.98 (0.77--1.24)   0.14                                                    49                2.04 (0.32--13.00)   0.07                                                    62     1.07 (0.84--1.36)   0.91                                                    0      2.29 (0.38--13.69)   0.09                                                    59
   Caucasian                               1                                                 1.69 (0.77--3.71)   NA                                                      NA                0.15 (0.01--2.98)    NA                                                      NA     2.15 (0.94--4.94)   NA                                                      NA     0.18 (0.01--3.52)    NA                                                      NA

Number of comparisons;

test for heterogeneity.

NA, not applicable; CI, confidence interval; OR, odds ratio; Ht, heterozygote; WT Ho, wild-type homozygote; VR, variant.
